Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy

Phase 1

Completed

• Conditions: Pharmacokinetics
• Interventions: Drug: Cefiderocol

• Registration Number: NCT05373615
• Lead Sponsor: Hartford Hospital

Brief Summary

Continuous renal replacement therapies (CRRT) such as continuous venovenous hemofiltration are used to provide renal support for critically ill patients with acute kidney injury (AKI), particularly patients who are hemodynamically unstable. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how CRRT affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving CRRT.

Detailed Description

This is a prospective, multi-center, open-label, Phase 1b, pharmacokinetic study of Cefiderocol in 16 critically ill patients receiving CRRT support. Informed consent will be collected from all study participants, legal authorized representative, or their next of kin in order to participate. This is not a treatment study; all participants will receive standard of care antibiotics which may include cefiderocol as necessary to treat any current infection.

Study Timeline

• Study First Submitted: 2022-05-10
• Study First Submitted QC: 2022-05-12
• Study First Posted: 2022-05-13
• Study Start: 2022-07-25
• Primary Completion: 2024-11-20
• Study Completion: 2024-11-20
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-13
• Last Update Posted: 2024-12-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

1. Age 18 years or older;
2. Receiving CRRT including CVVH, CVVHD, and CVVHDF support.

Exclusion Criteria

1. Females who are pregnant or breast-feeding;
2. History of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful re-exposure is not a contraindication);
3. A hemoglobin less than 8 gm/dl at baseline;
4. Acute liver injury, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal, or AST or ALT > 3 times the upper limit of normal with an associated total bilirubin > 2 times upper limit of normal;
5. Any rapidly-progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator);
6. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cefiderocol	Cefiderocol	Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate

Primary Outcome Measures

Name	Time	Method
Cefiderocol concentration	8 to 12 hours	The total and free plasma concentration of cefiderocol over time
Cefiderocol clearance	8 to 12 hours	The Clearance in liters/hour of Cefiderocol from the plasma
Cefiderocol maximum concentration	8 to 12 hours	The maximum concentration of Cefiderocol from the plasma

Trial Locations

Locations (1)

Hartford Hospital; 🇺🇸 Hartford, Connecticut, United States